Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploiting evolutionary steering to induce collateral drug sensitivity in cancer.

Nature communications - 21 Apr 2020

Acar Ahmet, Nichol Daniel, Fernandez-Mateos Javier, Cresswell George D, Barozzi Iros, Hong Sung Pil, Trahearn Nicholas, Spiteri Inmaculada, Stubbs Mark, Burke Rosemary, Stewart Adam, Caravagna Giulio, Werner Benjamin, Vlachogiannis Georgios, Maley Carlo C, Magnani Luca, Valeri Nicola, Banerji Udai, Sottoriva Andrea

Abstract excerpt

Drug resistance mediated by clonal evolution is arguably the biggest problem in cancer therapy today. However, evolving resistance to one drug may come at a cost of decreased fecundity or increased sensitivity to another drug. These evolutionary trade-offs can be exploited using 'evolutionary steering' to control the tumour population and delay resistance. However, recapitulating cancer evolutionary dynamics...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clonal Evolution
Share to Computer Simulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Gefitinib

Share to Models, Theoretical

Share to Pyridones

Share to Pyrimidinones

Share to Stochastic Processes

Source

Open in PubMed Open full text

Identifiers

PMID: 32317663
DOI: 10.1038/s41467-020-15596-z
PMCID: PMC7174377

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploiting evolutionary steering to induce collateral drug sensitivity in cancer.PMID 32317663Read ↗

Exploiting evolutionary herding to control drug resistance in cancerSemantic proximity Read ↗

Quantitative measurement of phenotype dynamics during cancer drug resistance evolution using genetic barcodingSemantic proximity Read ↗

Understanding the role of phenotypic switching in cancer drug resistance.Semantic proximity Read ↗

Joint analysis of mutational and transcriptional landscapes in human cancer reveals key perturbations during cancer evolution.Semantic proximity Read ↗

Epigenetic heritability of cell plasticity drives cancer drug resistance through one-to-many genotype to phenotype mappingSemantic proximity Read ↗

Computational quantification and characterization of independently evolving cellular subpopulations within tumors is critical to inhibit anti-cancer therapy resistanceSemantic proximity Read ↗

Epigenetic Heritability of Cell Plasticity Drives Cancer Drug Resistance through a One-to-Many Genotype-to-Phenotype Paradigm.Semantic proximity Read ↗

Clonal evolution in cancer.Semantic proximity Read ↗

Clone-level multi-modal prediction of tumour drug responseSemantic proximity Read ↗

Multi-omic lineage tracing predicts the transcriptional, epigenetic and genetic determinants of cancer evolution.Semantic proximity Read ↗

Leveraging Experimental Evolution to Extract Predictive Collateral Drug Response Signatures in Ewings SarcomaSemantic proximity Read ↗

Programmed evolution: Using asexual gene drives to sculpt tumor populations and combat genetic diversitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.